08:18 AM EDT, 05/29/2024 (MT Newswires) -- Assertio Therapeutics (ASRT) said Wednesday that Brendan P. O'Grady has been named chief executive and to its board, effective immediately.

He succeeds board member Heather Mason, who had been interim CEO for the past few months.

O'Grady was most recently CEO of Glenmark Pharmaceuticals' global formulation business, Assertio ( ASRT ) said.

Price: 1.0097, Change: +0.01, Percent Change: +0.97